The SOLO2 clinical trial was a Phase III, double-blinded, randomized, placebo-controlled study that evaluated the use of olaparib as maintenance therapy in platinum-sensitive, relapsed ovarian cancer patients with a BRCA1/2 mutation who had received at least two lines of previous chemotherapy (Pujade-Lauraine et al., 2017). Here, BRCA1 is linked to ovarian carcinoma.